| Biomarker ID | 595 |
| PMID | 21323568 |
| Year | 2011 |
| Biomarker | sVEGFR1 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Downregulated in Docetaxel + Imatinib arm |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- Neurophilin interactions with VEGF and VEGF receptor,Signaling by VEGF, HIF-2-alpha transcription factor network, S1P/S1P3 pathway, Actions of nitric oxide in the heart |
| Experiment | Docetaxel + placebo VS Docetaxel + imatinib |
| Type of Biomarker | Predictive |
| Cohort | 116 patients having metastatic castration-resistant prostate cancer were chosen for this study and plasma samples were colllected from 88 patients. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.001 |
| Method Used | Multiplex cytokine assay |
| Clinical | No |
| Remarks | To find out the predictive value of imatinib. Based on a piecewise linear regression model for change in concentration of each cytokine as a function of the probability of change in p-PDGFR in vivo, only the dynamics of PIGF (P<0.0001) and soluble c-kit (P<0.0001) differed with imatinib therapy. Values shown in regulation represent: Means and Standard Deviations (in Parentheses) of Change from Baseline to Course 2 Day 1 of Chemotherapy for Each Cytokine Variable, Within Each Treatment Arm. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | FLT1 |